4th of July Sale: Create a Free Seeking Alpha Account
Our 20% off sale is extended to 4th of July! Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

or
By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

APUS Apimeds Pharmaceuticals US, Inc.
Stock Price & Overview

$1.74-0.03 (-1.69%)4:00 PM 07/02/25
NYSE | $USD | Post-Market: $1.83 +0.09 (+5.17%) 7:49 PM

APUS Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

APUS Analysis

APUS News

Latest Headlines

People Also Follow

Similar to APUS

ETFs Holding APUS

APUS Company Profile

Apimeds Pharmaceuticals US, Inc. logo
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey.
Sector
Health Care
Industry
Biotechnology
Employees
2
Founded
2020
Address
  • 2 East Broad Street
  • 2nd Floor
  • Hopewell, NJ, 08525
  • United States
Phone Number
808 209 7887
Website
www.apimedsus.com
Hide

APUS Revenue

More On Revenue »

Earnings Revisions

Profitability

Momentum

Capital Structure

Dividends

APUS does not currently pay a dividend.

APUS Ownership

APUS Peers

Risk

Technicals

APUS SEC Filings

See All SEC Filings »

Press Releases

APUS Income Statement

APUS Balance Sheet

APUS Cash Flow Statement

APUS Long Term Solvency

Apimeds Pharmaceuticals US, Inc. (APUS) Frequently Asked Questions